Login / Signup

Changes in glycemic control and skeletal muscle mass indices after dapagliflozin treatment in individuals with type 1 diabetes mellitus.

Yuta YoshimuraYoshitaka HashimotoHiroshi OkadaMaya TakegamiHanako NakajimaTomoki MiyoshiTakashi YoshimuraMasahiro YamazakiYoshitaka HashimotoMichiaki Fukui
Published in: Journal of diabetes investigation (2023)
Dapagliflozin treatment of individuals with type 1 diabetes, particularly non-obese individuals and older men, might result in loss of skeletal muscle mass. However, good glycemic control during treatment might prevent the onset and progression of sarcopenia.
Keyphrases
  • glycemic control
  • type diabetes
  • skeletal muscle
  • blood glucose
  • weight loss
  • insulin resistance
  • middle aged
  • physical activity
  • combination therapy
  • community dwelling
  • obese patients
  • smoking cessation